» Articles » PMID: 12893818

Identification and Characterization of E2F7, a Novel Mammalian E2F Family Member Capable of Blocking Cellular Proliferation

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2003 Aug 2
PMID 12893818
Citations 107
Authors
Affiliations
Soon will be listed here.
Abstract

The mammalian E2F family of transcription factors plays a crucial role in the regulation of cellular proliferation, apoptosis, and differentiation. Consistent with its biological role in a number of important cellular processes, E2F regulates the expression of genes involved in cell cycle, DNA replication, DNA repair, and mitosis. It has proven difficult, however, to determine the specific roles played by the various known family members in these cellular processes. The work presented here now extends the complexity of this family even further by the identification of a novel E2F family member, which we now term E2F7. Like the expression of the known E2F activators, E2F1, E2F2, and E2F3, the expression of E2F7 is growth-regulated, at least in part, through E2F binding elements on its promoter, and its protein product is localized to the nucleus and associates with DNA E2F recognition sites with high affinity. A number of salient features, however, make this member unique among the E2F family. First, the E2F7 gene encodes a protein that possesses two distinct DNA-binding domains and that lacks a dimerization domain as well as a transcriptional activation and a retinoblastoma-binding domain. In contrast to the E2F activators, E2F7 can block the E2F-dependent activation of a subset of E2F target genes as well as mitigate cellular proliferation of mouse embryo fibroblasts. These findings identify E2F7 as a novel member of the mammalian E2F transcription factor family that has properties of a transcriptional repressor capable of negatively influencing cellular proliferation.

Citing Articles

E2F1 and E2F7 regulate gastric cancer cell proliferation, respectively, through transcriptional activation and transcriptional repression of MYBL2.

Wu T, Jiang F, Wu F, Zheng G, Li Y, Wu L J Biol Chem. 2024; 301(1):108027.

PMID: 39613162 PMC: 11731210. DOI: 10.1016/j.jbc.2024.108027.


The roles of E2F7 in cancer: Current knowledge and future prospects.

Chen K, Lei H, Liu X, Wang S Heliyon. 2024; 10(14):e34362.

PMID: 39108857 PMC: 11301362. DOI: 10.1016/j.heliyon.2024.e34362.


RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in Wild-Type Chronic Lymphocytic Leukemia.

Aptullahoglu E, Nakjang S, Wallis J, Marr H, Marshall S, Willmore E Biomedicines. 2024; 12(7).

PMID: 39061962 PMC: 11274024. DOI: 10.3390/biomedicines12071388.


In vivo CRISPR/Cas9-mediated screen reveals a critical function of TFDP1 and E2F4 transcription factors in hematopoiesis.

Tran N, Graf R, Acevedo-Ochoa E, Trombke J, Weber T, Sommermann T Leukemia. 2024; 38(9):2003-2015.

PMID: 39043964 PMC: 11347378. DOI: 10.1038/s41375-024-02357-w.


Unlocking the Power of Transcriptomic Biomarkers in Qualitative and Quantitative Genotoxicity Assessment of Chemicals.

Thienpont A, Cho E, Williams A, Meier M, Yauk C, Rogiers V Chem Res Toxicol. 2024; 37(3):465-475.

PMID: 38408751 PMC: 10952014. DOI: 10.1021/acs.chemrestox.3c00318.